OTR3 focuses on high potential programs
including award winning key projects.
OTR3 focuses on key development projects with high potential, with the aim of exploiting the versatility of the RGTA® technology to provide to patients new healthcare products that really matter.
The following development programs, relying on the regenerating potential of RGTA® molecules, are just only a fraction of the technology’s potential, and are to date the closer to market.
The excellence and potential of OTR3’s Pipeline has been confirmed by awards and grants (H2020 SME Instrument, Medicen Label, ANR grant, INCA)
Acute ischemic stroke
Funding
Publications
Brain protection after radiotherapy
Funding
INCa-Brain-Matrix : Matrix Therapy against Radiotherapy-Induced Brain damage and Cognitive deficits (Brain-MATRiX)
Alzheimer’s disease and tauopathies
Publications
